BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ventac Partners Guides Miacom Diagnostics GmbH to Complete Management Buyout


2/21/2013 9:12:28 AM

DÜSSELDORF, Germany--(BUSINESS WIRE)--Ventac Partners announces today that it has successfully facilitated the completion of Miacom Diagnostic’s management buyout from the German-Finnish investor Inveni Capital Oy. As of the end of January, 2013, the majority of the company is owned and controlled by its current management team. The successful transaction facilitated by Ventac Partners new Düsseldorf office continues the firm’s stellar track record of molding life science, technology companies into viable commercial entities. Miacom specializes in IVD tests for detecting acute systemic diseases, such as sepsis and pneumonia. The company, headquartered in Düsseldorf, Germany, was founded in 2006 with a promising core technology and a vision to apply it toward faster and better methods to identify pathogens and determine their resistance to antibiotics. Inveni Capital’s investment has funded the development and commercialization of the company’s initial molecular diagnostic product line currently sold in the European market.

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES